VIR vs. RXRX

Last updated Apr 2, 2026

Compare and contrast key facts about Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

VIR vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

VIR vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
VIR Vir Biotechnology, Inc.	49.59%	-17.85%	-27.04%	-60.25%	-39.55%	-9.72%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Fundamentals

Market Cap VIR : $1.26B RXRX : $1.61B
EPS VIR : -$3.15 RXRX : -$1.39
PS Ratio VIR : 18.27 RXRX : 19.03
PB Ratio VIR : 1.64 RXRX : 1.43
Total Revenue (TTM) VIR : $68.56M RXRX : $74.56M
Gross Profit (TTM) VIR : $68.53M RXRX : $3.73M
EBITDA (TTM) VIR : -$459.23M RXRX : -$579.69M

Returns By Period

In the year-to-date period, VIR achieves a 49.59% return, which is significantly higher than RXRX's -25.18% return.

VIR

• 1D: 0.67%
• 1M: -3.43%
• YTD: 49.59%
• 6M: 58.25%
• 1Y: 45.95%
• 3Y*: -27.09%
• 5Y*: -28.88%
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VIR vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VIR

VIR Risk / Return Rank: 64
VIR Sharpe Ratio Rank: 63
VIR Sortino Ratio Rank: 66
VIR Omega Ratio Rank: 61
VIR Calmar Ratio Rank: 65
VIR Martin Ratio Rank: 63

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VIR vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VIR	RXRX	Difference
Sharpe ratio Return per unit of total volatility	0.64	-0.48	+1.11
Sortino ratio Return per unit of downside risk	1.45	-0.32	+1.77
Omega ratio Gain probability vs. loss probability	1.17	0.97	+0.20
Calmar ratio Return relative to maximum drawdown	1.15	-0.72	+1.88
Martin ratio Return relative to average drawdown	2.44	-1.43	+3.87
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VIR vs. RXRX - Sharpe Ratio Comparison

The current VIR Sharpe Ratio is 0.64, which is higher than the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of VIR and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VIR	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.64	-0.48	+1.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.40	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	-0.40	+0.33

Correlation

The correlation between VIR and RXRX is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

VIR vs. RXRX - Dividend Comparison

Neither VIR nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VIR vs. RXRX - Drawdown Comparison

The maximum VIR drawdown since its inception was -94.85%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for VIR and RXRX.

Drawdown Indicators

	VIR	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-94.85%	-93.13%	-1.72%
Max Drawdown (1Y) Largest decline over 1 year	-33.95%	-58.17%	+24.22%
Max Drawdown (5Y) Largest decline over 5 years	-92.15%	—	—
Current Drawdown Current decline from peak	-89.14%	-92.60%	+3.46%
Average Drawdown Average peak-to-trough decline	-67.01%	-74.78%	+7.77%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.04%	29.48%	-13.44%

Volatility

VIR vs. RXRX - Volatility Comparison

Vir Biotechnology, Inc. (VIR) has a higher volatility of 17.00% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VIR	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.00%	14.66%	+2.34%
Volatility (6M) Calculated over the trailing 6-month period	52.42%	54.53%	-2.11%
Volatility (1Y) Calculated over the trailing 1-year period	72.61%	83.97%	-11.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	72.88%	94.52%	-21.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.01%	94.52%	+2.49%

Financials